Our hypotheses were: (1) atypical MS cases would have worse outcomes than typical cases in terms of disability, lesion load and brain atrophy and (2) that a proportion of atypical cases would be positive for AQP4 or MOG antibodies. The gene discussed is MOG; the disease is myeloid sarcoma.